ImmuCell (NASDAQ:ICCC) focuses on developing and producing products that improve animal health and productivity in the dairy and beef industries. Known for its innovative approach, the company mainly operates within the bovine health sector, striving to provide effective solutions for mastitis, one of the most costly diseases affecting dairy cows. Among its flagship projects is First Defense®, a unique product designed to prevent this disease in newborn calves, showcasing ImmuCell's dedication to enhancing immune responses without relying on antibiotics. With a strong belief in sustainable and responsible animal care, ImmuCell’s objectives include continuing to expand its product line, improving farm profitability and animal welfare, and addressing the pressing issue of antibiotic resistance in agriculture.